Molecular biology and colorectal cancer management

被引：0

作者：

Manceau, G. ^{[1
]}

Laurent-Puig, P. ^{[1
]}

Blons, H. ^{[1
]}

机构：

[1] Univ Paris 05, Inserm UMR Bases Mol Reponse Xenobiot S775, F-75270 Paris 06, France

来源：

ONCOLOGIE | 2012年 / 14卷 / 01期

关键词：

Colorectal cancer; Molecular biology; Microsatellite; Anti-EGFR antibodies; KRAS; CETUXIMAB PLUS IRINOTECAN; MICROSATELLITE-INSTABILITY; LYNCH-SYNDROME; ADJUVANT CHEMOTHERAPY; 1ST-LINE TREATMENT; MUTATION STATUS; KRAS; FLUOROURACIL; EFFICACY; IDENTIFICATION;

D O I：

10.1007/s10269-012-2109-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In current clinical practice, increasing number of situations make necessary the use of molecular biology tests to help clinicians in charge of patients with colorectal cancer (CRC) in their therapeutic decisions: indication of adjuvant chemotherapy after colorectal surgery, treatment choice in case of unresectable metastatic CRC. Advances in pharmacogenetics allowed a better characterization of inherited causes of CRC and to identify prognostic and predictive factors for different treatments. The purpose of this article is to present the recent advances in the use of molecular biology in case of suspected Lynch syndrome and indication of anti-EGFR antibodies. To cite this journal: Oncologie 14 (2012).

引用

页码：45 / 51

页数：7

共 28 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[3] Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view [J].

Blons, H. ;

Laurent-Puig, P. .

BULLETIN DU CANCER, 2009, 96 :S47-S56

[4] Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer [J].

Bokemeyer, Carsten ;

Bondarenko, Igor ;

Makhson, Anatoly ;

Hartmann, Joerg T. ;

Aparicio, Jorge ;

de Braud, Filippo ;

Donea, Serban ;

Ludwig, Heinz ;

Schuch, Gunter ;

Stroh, Christopher ;

Loos, Anja H. ;

Zubel, Angela ;

Koralewski, Piotr .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (05) :663-671

[5] Cancer genetics: estimation of the needs of the population in France for the next ten years [J].

Bonaiti-Pellie, C. ;

Andrieu, N. ;

Arveux, P. ;

Bonadona, V. ;

Buecher, B. ;

Delpech, M. ;

Jolly, D. ;

Julian-Reynier, C. ;

Luporsi, E. ;

Nogues, C. ;

Nowak, F. ;

Olschwang, S. ;

Orsi, F. ;

Pujol, P. ;

Saurin, J-C. ;

Sinilnikova, O. ;

Stoppa-Lyonnet, D. ;

Thepot, F. .

BULLETIN DU CANCER, 2009, 96 (09) :875-900

[6] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[7] KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab [J].

De Roock, W. ;

Piessevaux, H. ;

De Schutter, J. ;

Janssens, M. ;

De Hertogh, G. ;

Personeni, N. ;

Biesmans, B. ;

Van Laethem, J. -L. ;

Peeters, M. ;

Humblet, Y. ;

Van Cutsem, E. ;

Tejpar, S. .

ANNALS OF ONCOLOGY, 2008, 19 (03) :508-515

[8] Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis [J].

Des Guetz, Gaetan ;

Schischmanoff, Olivier ;

Nicolas, Patrick ;

Perret, Gerard-Yves ;

Morere, Jean-Francois ;

Uzzan, Bernard .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (10) :1890-1896

[9] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[10] PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients [J].

Frattini, M. ;

Saletti, P. ;

Romagnani, E. ;

Martin, V. ;

Molinari, F. ;

Ghisletta, M. ;

Camponovo, A. ;

Etienne, L. L. ;

Cavalli, F. ;

Mazzucchelli, L. .

BRITISH JOURNAL OF CANCER, 2007, 97 (08) :1139-1145

← 1 2 3 →